Pfizer taps Effector Therapeutics for its anticancer translation inhibitor
Thursday, January 9, 2020 - 08:10
in Health & Medicine
Effector's eIF4E inhibitor is designed to halt the output of cancer-driving mutations in the PI3K pathway